Olipharma Successfully Recognized as Suzhou Municipal Engineering Technology Research Center for Nucleic Acid Drug Development and Analysis Platform

Olipharma

About Olipharma

Suzhou Olipharma Technology Co., Ltd. is a professional pharmaceutical nucleic acid CDMO company that provides customers with "one-stop" services including nucleic acid drug discovery, laboratory R&D, process and analytical development, CMC services, API production, and drug registration. The technical team of Olipharma comes from one of the earliest teams in China to engage in the development of nucleic acid drug manufacturing processes and CMC research, possessing extensive experience in project development and product registration. Currently, the company has established four industry-leading core technology platforms: solid-phase nucleic acid synthesis, chemical modification and conjugation, process development and analysis, and CMC pharmaceutical research. It has also initiated in-depth collaborations with multiple pharmaceutical and biotechnology companies both domestically and internationally.

In 2023, the company's 3,000㎡ pilot platform compliant with GMP standards officially began offering services, focusing on helping clients address key challenges such as the scale-up of small nucleic acid drug production processes and CMC pharmaceutical research. The company will continue to provide compliant, high-quality, reliable, and efficient services to help clients enhance R&D efficiency, accelerate product registration and market entry, jointly supporting the entire process of small nucleic acid drugs from preclinical to commercial production.